Fortress Biotech, Inc. · NASDAQ:FBIO
Fortress Biotech — Coronado Biosciences — Investor Presentation (August 2013)
84 slides from Fortress Biotech's investor presentation, Aug 30, 2013
Slide 1: coronado
coronado BIOSCIENCES
Slide 2: Coronado
4a >» Coronado BIOSCIENCES bg
Slide 3: Developing Unique Products for Autoimmune Diseases and Cancer
Developing Unique Products for Autoimmune Diseases and Cancer (NASDAQ: CNDO) September 2013 Harlan F. Weisman, MD Chairman and CEO Exhibit 99.1
Slide 4: Slide 4
Slide 5: Slide 5
Slide 6: Slide 6
Slide 7: Slide 7
Slide 8: Slide 8
Slide 9: Slide 9
Slide 10: Bo] fr
9 Bo] fr lt Qi: Ol: 9 16)
Slide 11: coronado
ll coronado
Slide 12: coronado
ll coronado
Slide 13: Slide 13
Slide 14: Slide 14
Slide 15: Slide 15
Slide 16: Rising incidence of autoimmune diseases
Multiple sclerosis Type 1 diabetes x 2 By 2 5 3 a 2 2 5 e £ I 2 8 2 5 3 3 & 1960 1970 1980 1990 2000
Slide 17: Rising incidence of autoimmune diseases
= 400-4 Crohn's B. disease 2 3 2 eclress G 3004 2 € 5 & E ype 1 %5 2007 diabetes g 8 5 3 Asthma 3 & 1950 1960 1970 1980 1990 2000 coronado FIOSGIENEES
Slide 18: Rising incidence of autoimmune diseases
= 400-4 Crohn's B. disease 2 3 2 eclress G 3004 2 € 5 & E ype 1 %5 2007 diabetes g 8 5 3 Asthma 3 & 1950 1960 1970 1980 1990 2000 coronado FIOSGIENEES
Slide 19: . ye sy
. ye sy HE Moderate ; Bh Low. By. Moderate coronado
Slide 20: Moderate
Moderate By Low. \ coronado y
Slide 21: Moderate
Moderate By Low. \ coronado y
Slide 22: Helminthic Exposures
Helminthic Exposures Ny seoouteYy T Cells Th2 Cells cps gone: 1L10- Change Intestinal Macrophage Flora —_—, and — t Helminthic Exposures Induce coronado Block Effector T Cell Proliferation, IFNy and IL17 Secretion
Slide 23: Helminthic Exposures
Helminthic Exposures Ny Regul: a T Cetts Th2 Cells cp4 cps a (Foxp3) Jf (Foxp3) 1L4 -- TGFB, IL10- Other? wane ee Block Effector T Cell oo) > Proliferation, “ere IFNy and IL17 Effector DG : Effector T Cells 4 Secretion Change ov = Intestinal Macrophaae Flora a a and —— t Helminthic Exposures Induce
Slide 24: Helminthic Exposures
Helminthic Exposures Ny Regul: a T Cetts Th2 Cells cp4 cps a (Foxp3) Jf (Foxp3) 1L4 -- TGFB, IL10- Other? wane ee Block Effector T Cell oo) > Proliferation, “ere IFNy and IL17 Effector DG : Effector T Cells 4 Secretion Change ov = Intestinal Macrophaae Flora a a and —— t Helminthic Exposures Induce
Slide 25: coronado
coronado
Slide 26: Slide 26
Slide 27: Slide 27
Slide 28: Percent Response and Remission at Weeks
Percent Response and Remission at Weeks 12 and 24 g Gy = id & 6 Rg 12 Weeks 24 Weeks Dremission GResponse coronado
Slide 29: Percent Response and Remission at Weeks
100 Percent Response and Remission 90 at Weeks 12 and 24 80 70 60 50 40 30 20 10 ot 2 % of Patients {n=29) 12 Weeks 24 Weeks Dremission Response coronado
Slide 30: Percent Response and Remission at Weeks
100 Percent Response and Remission 90 at Weeks 12 and 24 80 70 60 50 40 30 20 10 ot 2 % of Patients {n=29) 12 Weeks 24 Weeks Dremission Response coronado
Slide 31: (sesuodsas %)
(sesuodsas %) 7291)-0)]-JUS}U] 9 xe) fs] 5 9 16)
Slide 32: (sesuodsas %)
(sesuodsas %) 7291}-0)-JUS}U]
Slide 33: (sesuodsas %)
(sesuodsas %) 7291}-0)-JUS}U]
Slide 34: Slide 34
Slide 35: Slide 35
Slide 36: Slide 36
Slide 37: cred
cred wllbetnfected treated moe infected untreated ‘ood spin QO 12 24 36 48 60 72 84 ye a u Led N Es | suse] Z| Suisiepug pue man oO ne) (e) 5 = fe) 16) O 412 24 36 48 60 72 84 wy can) SUOQEQIIIENY JO
Slide 38: 9.9 eteetininfected
9.9 35 eteetininfected Og we wi infectad treated 2 5 3 ss infected untreated 5 07 FA 8 06 aes £° e S05 #2 oS 2 04 £15 .) = 3 03 3 Q & i § 0.2 2 O1 2 0.8 0 i) 0 12 24 36 48 60 72 84 OQ 12 24 36 48 60 72 84 Months Months
Slide 39: 9.9 eteetininfected
9.9 35 eteetininfected Og we wi infectad treated 2 5 3 ss infected untreated 5 07 FA 8 06 aes £° e S05 #2 oS 2 04 £15 .) = 3 03 3 Q & i § 0.2 2 O1 2 0.8 0 i) 0 12 24 36 48 60 72 84 OQ 12 24 36 48 60 72 84 Months Months
Slide 40: New gadolinium-enhancing MRI brain lesions
New gadolinium-enhancing MRI brain lesions a ts AE} a cH s 3 a < . ° . o 2 £ 3 =< < al > a = 2 month baseline 3 months treatment 2 month post-treatment coronado
Slide 41: New gadolinium-enhancing MRI brain lesions
New gadolinium-enhancing MRI brain lesions Median Number of New Lesions Loo N w cS uw oO fo} 2 month baseline 3 months treatment 2 month post-treatment coronado
Slide 42: New gadolinium-enhancing MRI brain lesions
New gadolinium-enhancing MRI brain lesions Median Number of New Lesions Loo N w cS uw oO fo} 2 month baseline 3 months treatment 2 month post-treatment coronado
Slide 43: coronado
coronado
Slide 44: Slide 44
Slide 45: Slide 45
Slide 46: Slide 46
Slide 47: q V Y
— & t 4 q V 4 Y V V v v V ' 3 coronado
Slide 48: q V Y
— & t 4 q V 4 Y V V v v V ' 3 coronado
Slide 49: Slide 49
Slide 50: Slide 50
Slide 51: Slide 51
Slide 52: coronado
coronado
Slide 53: coronado
coronado
Slide 54: coronado
coronado
Slide 55: Slide 55
Slide 56: Slide 56
Slide 57: Slide 57
Slide 58: coronado
coronado
Slide 59: coronado
coronado
Slide 60: coronado
coronado
Slide 61: Slide 61
Slide 62: Slide 62
Slide 63: Slide 63
Slide 64: Slide 64
Slide 65: Slide 65
Slide 66: Slide 66
Slide 67: Slide 67
Slide 68: Slide 68
Slide 69: Slide 69
Slide 70: coronado
coronado
Slide 71: coronado
coronado
Slide 72: coronado
coronado
Slide 73: Slide 73
Slide 74: Slide 74
Slide 75: Slide 75
Slide 76: Slide 76
Slide 77: Slide 77
Slide 78: Slide 78
Slide 79: Slide 79
Slide 80: Slide 80
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Coronado Biosciences — Investor Presentation (August 2013) on 6ix